Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma

被引：0

作者：

Vinita Akula ^{[1
]}

Lily Chen ^{[1
]}

Yusuf Acikgoz ^{[2
]}

Katherine Klein ^{[1
]}

Betul Gok Yavuz ^{[3
]}

Lokman Cevik ^{[4
]}

Tarik Demir ^{[5
]}

Ashish Manne ^{[2
]}

Ilyas Sahin ^{[6
]}

Ahmed Kaseb ^{[7
]}

Elshad Hasanov ^{[2
]}

机构：

[1] The University of Texas Health Science Center at Houston (UTHealth),Department of Internal Medicine

[2] The Ohio State University Comprehensive Cancer Center,Division of Medical Oncology, Department of Internal Medicine

[3] University of Missouri,Department of Medicine

[4] The Ohio State University Wexner Medical Center,Department of Pathology

[5] Northwestern University,Division of Hematology and Oncology Developmental Therapeutics Institute

[6] University of Florida,Division of Hematology & Oncology, Department of Medicine

[7] The University of Texas MD Anderson Cancer Center,Department of Gastrointestinal Medical Oncology

来源：

npj Precision Oncology | / 9卷 / 1期

关键词：

D O I：

10.1038/s41698-025-00846-4

中图分类号：

学科分类号：

摘要：

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HCC treatment is challenging; surgical resection is the primary curative treatment for early-stage disease, but recurrence rates are high. Immune checkpoint inhibitors (ICIs) are a promising neoadjuvant treatment that can reduce recurrence rates and mortality after surgery and achieve complete/partial responses. Clinical trials provide strong evidence for the efficacy and safety of ICI monotherapy for neoadjuvant HCC treatment.

引用

共 50 条

[41] Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
Zhang, Jin
Hu, Changwei
Xie, Xiaoxiao
Qi, Linzhi
Li, Chuanzhou
Li, Shangze
VACCINES, 2023, 11 (03)
[42] Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors
Lin, Zuyuan
Lu, Di
Wei, Xuyong
Wang, Jianguo
Xu, Xiao
AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (04): : 1085 - 1102
[43] Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
Yin, Xiaoqiang
Wu, Tongchui
Lan, Yadong
Yang, Wulin
BIOSCIENCE REPORTS, 2022, 42 (02)
[44] Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
Federico, Piera
Petrillo, Angelica
Giordano, Pasqualina
Bosso, Davide
Fabbrocini, Antonietta
Ottaviano, Margaret
Rosanova, Mario
Silvestri, Antonia
Tufo, Andrea
Cozzolino, Antonio
Daniele, Bruno
CANCERS, 2020, 12 (10) : 1 - 20
[45] Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma
Tamai, Yasuyuki
Fujiwara, Naoto
Tanaka, Takamitsu
Mizuno, Shugo
Nakagawa, Hayato
CANCERS, 2023, 15 (20)
[46] Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Rizzo, Alessandro
Cusmai, Antonio
Gadaleta-Caldarola, Gennaro
Palmiotti, Gennaro
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (04) : 333 - 339
[47] Liver injury by immune checkpoint inhibitors in patients with hepatocellular carcinoma.
Personeni, Nicola
Pressiani, Tiziana
Capogreco, Antonio
Dal Buono, Arianna
D'Alessio, Antonio
Prete, Maria Giuseppina
Smiroldo, Valeria
Bozzarelli, Silvia
Giordano, Laura
Aghemo, Alessio
Santoro, Armando
Rimassa, Lorenza
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[48] Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors
Zhang, Rujia
Zhao, Haoran
Wang, Peng
Guo, Zuoming
Liu, Chunxun
Qu, Zhaowei
BMC CANCER, 2023, 23 (01)
[49] Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
Xie, Qingqing
Zhang, Pengfei
Wang, Yuanyuan
Mei, Wuxuan
Zeng, Changchun
FRONTIERS IN ONCOLOGY, 2022, 12
[50] Lenvatinib With or Without Immune Checkpoint Inhibitors in Subsets of Advanced Hepatocellular Carcinoma
Teng, Yu-xian
Guo, Ping-Ping
Qin, Ke-Zhang
Chen, Kang
Papatheodoridis, George
Xiang, Bang-De
Mia, Liang
Zhong, Jian-Hong
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, 2022, 6 (01): : 25 - 29

← 1 2 3 4 5 →